King buys rights to sell abuse-resistant OxyContin

11/10/2005 |

King Pharmaceuticals and Pain Therapeutics say they have reached a deal to give King the rights to a new version of the painkiller OxyContin. King obtained the rights to the abuse-resistant version of the drug for a reported $150 million up front with an additional $150 million possibly due depending on the speed with which Remoxy moves through the regulatory process.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
San Jose, CA
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Teaching Associate (Hospitality Management)
University of Illinois at Urbana-Champaign
Urbana, IL
Director, Global Regulatory Affairs
Rodan and Fields, LLC
San Francisco, CA